Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Other Gross PP&E Adjustments (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Other Gross PP&E Adjustments readings, the most recent being -$37.8 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 330.29% to -$37.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$37.8 million, a 330.29% decrease, with the full-year FY2025 number at $20.3 million, up 702.26% from a year prior.
  • Other Gross PP&E Adjustments hit -$37.8 million in Q4 2025 for Enanta Pharmaceuticals, down from $20.3 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $20.3 million in Q3 2025 to a low of -$37.8 million in Q4 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$9.1 million (2021), compared with a mean of -$8.4 million.
  • The widest YoY moves for Other Gross PP&E Adjustments: up 702.26% in 2025, down 330.29% in 2025.
  • Enanta Pharmaceuticals' Other Gross PP&E Adjustments stood at -$19.4 million in 2021, then decreased by 21.32% to -$23.5 million in 2022, then grew by 9.33% to -$21.3 million in 2023, then surged by 176.98% to $16.4 million in 2024, then crashed by 330.29% to -$37.8 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$37.8 million (Q4 2025), $20.3 million (Q3 2025), and $19.6 million (Q2 2025) per Business Quant data.